Solventum vs Teleflex
SOLV and TFX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SOLV and TFX compare
Solventum is the larger company, worth 2.3 times as much as Teleflex ($15.1B against $6.5B).
On earnings, Teleflex is cheaper: it trades at 18.6× trailing earnings, against 99.8× for Solventum.
Teleflex grew revenue faster over the last twelve months (20.9% versus −2.8% for Solventum).
Teleflex keeps more of each dollar of sales as profit, with a net margin of 13.5% compared with 1.9% at Solventum.
Teleflex pays a dividend yielding 0.89%; Solventum does not pay one.
Teleflex scores higher on the StockData Score (17 against 6 for Solventum), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SOLV | TFX |
|---|---|---|
| Size and price | ||
| Market cap | $15.1B | $6.5B |
| Share price | $88.81 | $153.15 |
| Change, 1 year | 20.2% | 36.4% |
| Change, 5 years | – | −52.0% |
| Beta (5Y) | 0.51 | 0.82 |
| Employees | 10K | 16K |
| StockData Score | ||
| Total score | 6 | 17 (better) |
| Valuation score | 1 | 6 (better) |
| Growth score | 2 | 2 |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 99.8× | 18.6× (better) |
| P/S | 1.9× (better) | 2.9× |
| P/B | 3.1× | 1.9× (better) |
| EV/EBITDA | 20.2× | 18.2× (better) |
| P/FCF | – | 26.7× |
| PEG | 22.14 | – |
| FCF yield | 0.00% | 3.7% (better) |
| Fair value | $45.74 | $215.83 |
| Margin of safety | −94.2% | 29.0% (better) |
| Growth | ||
| Revenue growth (TTM) | −2.8% | 20.9% (better) |
| Revenue growth, 5Y average | – | −4.7% |
| Net income growth (TTM) | −89.8% | – |
| EPS growth (TTM) | −89.8% | – |
| Profitability | ||
| Gross margin | 54.8% | 58.3% (better) |
| Operating margin | 5.6% | 9.4% (better) |
| Net margin | 1.9% | 13.5% (better) |
| FCF margin | 0.00% | 10.8% (better) |
| Return on equity | 3.2% | 8.3% (better) |
| Return on invested capital | 4.7% (better) | 3.1% |
| Financial health | ||
| Debt / equity | 1.05 | 0.46 (better) |
| Net debt / EBITDA | 4.74 | 2.82 (better) |
| Interest coverage | – | 2.1× |
| Current ratio | 1.03 | 2.01 (better) |
| Altman Z-score | 1.85 | 2.01 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.89% |
| Payout ratio | – | 19.3% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 8.6% |
| Shareholder yield | 0.00% | 9.4% (better) |
| Ownership | ||
| Held by institutions | 75.0% | 113% |
| Held by insiders | 30.3% | 0.73% |
| Insider net buying, 12 months | $100K | – |
| Superinvestors holding | 2 (better) | 1 |
| Short interest, % of float | 4.3% | 9.7% |
Go deeper
- SOLV stock overview
- SOLV income statement
- SOLV valuation and score
- TFX stock overview
- TFX income statement
- TFX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.